Action Required: Password Reset on Next Login
As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.
To reset your password, please visit the Reset Password page.
We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Saliogen Therapeutics Inc.
Headquarters: Cambridge, MA, United States of America
Website: https://saliogen.com/
Year Founded: 2020
Status: Private
See Emerging Company Profile .
BioCentury | Aug 20, 2024
Management Tracks
Toraishi steps down from Rakuten Medical as co-CEO
Plus: SalioGen hired Kalliopi Stasi as CMO and updates from PepGen, Cidara and Bio-Rad
BioCentury | Jul 5, 2024
Product Development
LNP innovation: tissue specificity, aided by AI
How LNP companies delivering nucleic acids are cracking the tissue tropism problem, and finding freedom to operate
BioCentury | May 22, 2024
Management Tracks
FDA vet Singh joining CRDO Precision for Medicine
Plus: de Moerlooze to depart Bavarian and updates from Engitix, Actio and Oruka
BioCentury | Sep 11, 2023
Management Tracks
Sanofi alum Sibold named CEO at Madrigal
Plus: Fenimore to succeed Landry as Regeneron CFO and updates from SpringWorks, SalioGen, Oxular, Solu, Flagship, Oculis
BioCentury | Jan 6, 2023
Emerging Company Profile
BioCentury’s 2022 class of emerging companies
A snapshot of gene therapy and CAR T innovation, the emergence of protein stabilization, and new thinking in neurology
BioCentury | Jul 21, 2022
Management Tracks
Versanis recruits Pruzanski as CEO, adds Maraganore, Duncan to board
Plus BMS’s new pricing SVP and updates from Forbion, Nuvalent and more
BioCentury | Mar 30, 2022
Emerging Company Profile
SalioGen: genome editing without viruses or nucleases
The Cambridge, Mass.-based biotech is using mammalian enzymes to insert DNA into the genome without causing breaks
BioCentury | Jan 19, 2022
Management Tracks
Interim no more: Zhang assumes Overland’s CEO post; Maraganore, Ho join as advisers
Plus: Merck KGaA strategy, R&D execs; and updates from CureVac, Exo, Krystal and more
BioCentury | Jan 6, 2022
Finance
Jan. 5 Quick Takes: Eventide leads mega-round by Korro
Plus Saliogen raises $115M series B and updates from
BioCentury | Nov 10, 2021
Management Tracks
Riva, alum of Gilead, Novartis, joins newco Intima as CEO
Maraganore, McClellan, Lo to advise SalioGen, plus
Items per page:
1 - 10 of 11